SCHEMBL5999342

SCHEMBL5999342

CCOC(=O)[C@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)OCC

nearest known ligand 0.81

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 18/20 0.81
PPARG P37231 13/20 0.81
PPARD Q03181 7/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365635 1.00 PPARA (0.81) PPARAPPARGPPARD
SCHEMBL5994086 1.00 PPARA (0.81) PPARAPPARGPPARD
SCHEMBL5992773 0.91 PPARA (0.67) PPARAPPARGPPARD
Tesaglitazar SCHEMBL16594 0.90 PPARA (1.00) PPARAPPARGPPARD
Tesaglitazar SCHEMBL600880 0.90 PPARA (1.00) PPARAPPARGPPARD
SCHEMBL5368994 0.90 PPARA (1.00) PPARAPPARGPPARD
Tesaglitazar SCHEMBL3162078 0.90 PPARA (1.00) PPARAPPARGPPARD
Tesaglitazar SCHEMBL13602606 0.90 PPARA (1.00) PPARAPPARGPPARD
SCHEMBL5991979 0.90 PPARG (0.66) PPARAPPARGPPARD
SCHEMBL7238281 0.89 PPARA (0.68) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090082441-A1 DEUTERIUM-ENRICHED TESAGLITAZAR PROTIA, LLC (US) 2009-03-26 US disclosed
US-20090082441-A1 DEUTERIUM-ENRICHED TESAGLITAZAR PROTIA, LLC (US) 2009-03-26 US disclosed
US-20060040979-A1 3-Aryl-2-hydroxypropionic acid derivative I ANDERSSON KJELL 2006-02-23 US disclosed
US-20040229946-A1 New 3-aryl-2-hydroxypropionic acid derivative I ANDERSSON KJELL (SE) 2004-11-18 US disclosed
US-6660879-B2 Use of the compound in clinical conditions associated with insulin resistance. ASTRAZENECA AB (SE) 2003-12-09 US disclosed
EP-1084103-B1 NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE (I) ASTRAZENECA AB (SE) 2003-08-06 EP disclosed
US-20030027859-A1 3-aryl-2-hydroxypropionic acid derivative I ANDERSSON KJELL (SE) 2003-02-06 US disclosed
US-20010034371-A1 New 3-aryl-2-hydroxypropionic acid derivative I ANDERSSON KJELL (SE) 2001-10-25 US disclosed
US-6258850-B1 SULFONATE DERIVATIVES OF ETHER, ACIDS AS DRUGS ASTRAZENECA AB (SE) 2001-07-10 US disclosed
EP-1084103-A1 NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE (I) AstraZeneca AB (SE) 2001-03-21 EP disclosed
WO-1999062872-A1 NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE (I) ASTRAZENECA AB (SE) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034371-A1 New 3-aryl-2-hydroxypropionic acid derivative I GPR119, IRS1, INSR PPARA 79/4885PPARG 144/4885PPARD 82/4885
US-20040229946-A1 New 3-aryl-2-hydroxypropionic acid derivative I GPR119, IRS1, INSR PPARA 79/4885PPARG 144/4885PPARD 82/4885
US-20090082441-A1 DEUTERIUM-ENRICHED TESAGLITAZAR GCGR, GLP1R, GIPR PPARA 854/4885PPARG 215/4885PPARD 318/4885
US-20030027859-A1 3-aryl-2-hydroxypropionic acid derivative I GPR119, IRS1, INSR PPARA 42/4885PPARG 95/4885PPARD 64/4885
US-20060040979-A1 3-Aryl-2-hydroxypropionic acid derivative I GPR119, IRS1, INSR PPARA 42/4885PPARG 95/4885PPARD 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.